A new pre-print Israeli study has found that people with natural immunity to COVID-19 could be 13 times less likely to contract the respiratory virus than those who were solely vaccinated against the disease.
Conducted by researchers at Maccabi Healthcare and Tel Aviv University,the yet-to-be peer-reviewed study found that when comparing individuals previously infected with the virus and those that received two jabs of the Pfizer-BioNTech shot,those with natural infection saw greater protection against the delta variant and breakthrough infection.
这项尚未经过同行评审的研究是由马卡比医疗保健和特拉维夫大学的研究人员进行的，研究发现，当比较先前感染过这种病毒的个体和那些接受过辉瑞生物技术注射的个体时，那些自然感染的个体对 delta 变异和突破性感染有更好的保护作用。
"SARS-CoV-2-naïve vaccinees had a 13.06-fold increased risk for breakthrough infection with the Delta variant compared to those previously infected,when the first event(infection or vaccination)occurred during January and February of 2021,"the study read."The increased risk was significant for symptomatic disease as well.When allowing the infection to occur at any time before vaccination(from March 2020 to February 2021),evidence of waning natural immunity was demonstrated,though SARS-CoV-2 naïve vaccinees had a 5.96-fold increased risk for breakthrough infection and a 7.13-fold increased risk for symptomatic disease."
该研究称:"当第一次事件(感染或接种)发生在2021年1月和2月时，接种 sars-cov-2天真疫苗的人突破性感染 Delta 变异的风险比先前感染的人增加了13.06倍。"。"增加的风险对症状性疾病也是显著的。在接种疫苗之前的任何时候(从2020年3月至2021年2月)允许感染发生时，自然免疫力下降的证据得到了证实，尽管接种 SARS-CoV-2天真疫苗的突破性感染风险增加了5.96倍，症状性疾病风险增加了7.13倍
The analysis also found that solely vaccinated individuals"were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected."
The study ultimately concluded that"natural immunity confers longer lasting and stronger protection against infection,symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2,compared to the BNT162b2 two-dose vaccine-induced immunity"and that"individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant."
这项研究最终得出结论认为,"与 BNT162b2两剂量疫苗诱导免疫相比，自然免疫提供了更持久和更强有力的保护，防止 SARS-CoV-2的 Delta 变异引起的感染、症状性疾病和住院治疗"，而且"同时感染了 SARS-CoV-2并接种了单剂量疫苗的个体获得了针对 Delta 变异的额外保护"
While the Israeli Health Ministry has indicated that the delta variant may be more likely to cause reinfection among recovered COVID-19 patients than previous variants,the data shows that natural immunity remains effective at offering robust protection against the virus.According to the Health Ministry,4,811 Israelis have been reinfected with coronavirus,which accounts for only 0.47 percent of the nation's total recoveries.
虽然以色列卫生部已经表明 delta 变异可能比之前的变异更有可能在已经康复的2019冠状病毒疾病患者中引起再感染，但是数据显示，自然免疫仍然有效地提供强有力的保护来抵御病毒。根据以色列卫生部的数据，4811名以色列人再次感染冠状病毒，这仅占以色列全部康复人数的0.47%。
Scott Gottlieb, MD on Twitter: "Israeli Health Ministry data suggests the Delta variant may be more effective at causing COVID reinfection among recovered patients than earlier strains of the coronavirus, but immunity from prior infection still appears to be protective. https://t.co/dAiFu0tEWP / Twitter"
Israeli Health Ministry data suggests the Delta variant may be more effective at causing COVID reinfection among recovered patients than earlier strains of the coronavirus, but immunity from prior infection still appears to be protective. https://t.co/dAiFu0tEWP
Israel remains one of the most vaccinated countries in the world,ranking third in doses administered per 100 people.
**By Shawn Fleetwood